

1 Title: Severe outcomes in unvaccinated COVID-19 cases <18 years during different variant
2 waves in Norway

3

4 Authors: Robert Whittaker (MSc) ^{a*}, Margrethe Greve-Isdahl (MD) ^a, Håkon Bøås (PhD) ^b,
5 Pål Suren (MD) ^c, Eirik Alnes Buanes (PhD) ^{d,e}, Lamprini Veneti (MSc) ^b

6 Family names are underlined.

7 a) Department of Infection Control and Vaccines, Norwegian Institute of Public Health,
8 Oslo, Norway.

9 b) Department of Infection Control and Preparedness, Norwegian Institute of Public
10 Health, Oslo, Norway.

11 c) Department of Child Health and Development, Norwegian Institute of Public Health,
12 Oslo, Norway.

13 d) Department of Anaesthesia and Intensive Care, Haukeland University Hospital,
14 Bergen, Norway.

15 e) Norwegian Intensive Care and Pandemic Registry, Haukeland University Hospital,
16 Bergen, Norway.

17 * Corresponding author: Robert Whittaker, Norwegian Institute of Public Health,
18 Lovisenberggata 8, 0456, Oslo, Norway; Phone: +47 21 07 63 93; Email:
19 Robert.Whittaker@fhi.no

20

21 Short title: Severe outcomes by variant, COVID-19 cases <18, Norway

22

23 Conflict of interest: The authors declare that they have no competing interests.

24

25 Funding: This research was undertaken as part of routine work at the Norwegian Institute of
26 Public Health. No specific funding was received.

27

28 Abbreviations

- 29 • VOC: Variant of concern
- 30 • SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- 31 • COVID-19: Coronavirus disease
- 32 • MIS-C: Multisystem inflammatory syndrome in children
- 33 • LoS: Length of stay
- 34 • ICU: intensive care unit
- 35 • aRR: Adjusted risk ratio
- 36 • CI: Confidence interval
- 37 • PCR: Polymerase chain reaction

38

39 **Article Summary**

40 We compare the risk of severe outcomes in unvaccinated COVID-19 cases <18 years between
41 waves of the SARS-CoV-2 Alpha, Delta and Omicron variant in Norway.

42

43 What's Known on This Subject

44 Currently, limited evidence suggests no clear difference in the risk of severe disease outcomes
45 among children infected with different SARS-CoV-2 variants. The risk of multisystem
46 inflammatory syndrome in children following infection with the Omicron variant has not been
47 quantified.

48

49 What This Study Adds

50 We find a lower risk of hospitalisation due to acute COVID-19 among cases <1 year in the
51 Delta and Omicron waves compared to the Alpha wave, and a lower risk of multisystem
52 inflammatory syndrome in the Omicron wave, in Norway.

53

54 Word count: 2,990

55 **Contributors' Statement Page**

56 Robert Whittaker conceptualised and designed the study, contributed to data cleaning and
57 linkage between the different registries, conducted the data analysis, drafted the initial
58 manuscript, and reviewed and revised the manuscript. Margrethe Greve-Isdahl and Pål Suren
59 conceptualised and designed the study, contributed interpretation of the results, and critically
60 reviewed the manuscript. Håkon Bøås conceptualised and designed the study, contributed to
61 data cleaning and interpretation of the results, and critically reviewed the manuscript. Eirik
62 Alnes Buanes conceptualised and designed the study, coordinated data collection to the
63 Norwegian Intensive Care and Pandemic Registry, contributed to interpretation of the results,
64 and critically reviewed the manuscript. Lamprini Veneti conceptualised and designed the
65 study, contributed to data cleaning, assisted with the data analysis, contributed to
66 interpretation of the results, and critically reviewed the manuscript. All authors approved the
67 final manuscript as submitted and agree to be accountable for all aspects of the work.

68 **Abstract**

69 **Objectives**

70 We used linked individual-level data from national registries to compare the risk of severe
71 outcomes among unvaccinated COVID-19 cases <18 years between waves of the SARS-
72 CoV-2 Alpha, Delta and Omicron variants in Norway.

73 **Methods**

74 Our outcomes were hospitalisation with acute COVID-19 or multisystem inflammatory
75 syndrome in children (MIS-C). We calculated adjusted risk ratios (aRR) with 95% confidence
76 intervals (CIs) using multivariable log-binomial regression, adjusting for variant wave,
77 demographic characteristics and underlying comorbidities.

78 **Results**

79 We included 10,538 Alpha (21 hospitalised with acute COVID-19, 7 MIS-C), 42,362 Delta
80 (28 acute COVID-19, 14 MIS-C) and 82,907 Omicron wave cases (48 acute COVID-19, 7
81 MIS-C). The risk of hospitalisation with acute COVID-19 in cases <1 year was lower in the
82 Delta (aRR: 0.28, 95% CI: 0.16–0.89) and Omicron wave (aRR: 0.41, 95% CI: 0.20–0.81),
83 compared to the Alpha wave. We found no difference in the risk for this outcome for Omicron
84 compared to Delta in any age group. The risk of MIS-C was lower in the Omicron wave
85 compared to the Alpha (aRR: 0.09, 95% CI: 0.03–0.27) and Delta wave (aRR: 0.26, 95% CI:
86 0.10–0.63).

87 **Conclusions**

88 We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19
89 among unvaccinated cases <18 years for Omicron compared to Delta, but a reduced risk
90 among cases <1 year in Omicron and Delta waves, compared to Alpha. Results also suggest a
91 decrease in the risk of MIS-C in the Omicron wave compared to the Alpha and Delta waves.

92 **Introduction**

93 From late 2020, the emergence and global spread of variants of concern (VOC) (1) of severe
94 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shaped the epidemiology of,
95 and ongoing response to, the coronavirus disease (COVID-19) pandemic. More transmissible
96 VOC have successively superseded their predecessors influencing transmission dynamics,
97 viral virulence and vaccine effectiveness (2-8). The emergence of the Omicron variant
98 (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation
99 B.1.1.529) in November 2021 instigated a new wave of infections globally (9).

100 Most children and adolescents with COVID-19 experience an asymptomatic or mild disease
101 course. However, a small proportion may develop severe disease that requires hospitalisation.
102 This may be due to acute COVID-19 or multisystem inflammatory syndrome in children
103 (MIS-C), a postinfectious complication of SARS-CoV-2 infection. Death is rare (10, 11).

104 There is currently limited evidence on whether the relative severity of COVID-19 in children
105 differs when infected with different VOC. Previous studies from England (5) and Denmark
106 (12) have not found clear evidence that the risk of hospitalisation among children and
107 adolescents infected with Omicron differed compared to the Delta variant (Pangolin
108 designation B.1.617.2). Preliminary data from the United States have suggested an increase in
109 upper respiratory complications among children since Omicron became dominant (13, 14).

110 Some studies comparing the risk of hospitalisation for the Delta variant to earlier VOC based
111 on reported cases have presented descriptive data for younger age groups, without providing
112 age-specific risk estimates (15, 16). Others have been restricted to hospital cohorts, with the
113 reported findings inconsistent between settings (17-19). A study from Denmark reported that
114 the risk of MIS-C did not change among unvaccinated cases during a wave of Delta infections
115 compared to when the wild-type SARS-CoV-2 variant was circulating (20).

116 Since the beginning of 2021, Norway has experienced three waves of COVID-19 cases when
117 different VOC were dominant; Alpha (pangolin designation B.1.1.7) (4), Delta (21) and
118 Omicron (8). We used linked individual-level data from national registries to compare the risk
119 of severe outcomes among unvaccinated COVID-19 cases <18 years between these three
120 variant waves.

121 **Methods**

122 **Study setting**

123 Norway (population 5.4 million, of whom 1.1 million <18 years) has had a broad testing
124 strategy for COVID-19 in children since autumn 2020. Four pillars of the national pandemic
125 response have been testing, isolation, contact tracing and quarantine. Through this framework
126 SARS-CoV-2 tests have been available free of charge for everyone, including those with mild
127 or no symptoms, close contacts and individuals in quarantine. Routine bi-weekly screening of
128 school children with rapid antigen tests in areas with high transmission was undertaken for
129 secondary school students from late-August 2021 and for primary school students from
130 November 2021 until January 2022. Positive rapid antigen tests were confirmed with PCR.
131 COVID-19 vaccine recommendations for children and adolescents in Norway and data on
132 vaccination coverage by age group over time are presented in supplement A, section 1. From
133 August 2021 there has been a general recommendation that all pregnant women in the second
134 or third trimester get vaccinated. For women with underlying risk factors, vaccination was
135 recommended in the first trimester (22).

136 **Data sources and study design**

137 We obtained data through the Norwegian national preparedness registry for COVID-19 (23).
138 The preparedness registry contains individual-level data from different central health
139 registries, national clinical registries, and other national administrative registries. It covers all

140 residents in Norway, and includes data on all laboratory-confirmed cases of COVID-19 in
141 Norway and all hospitalisations, intensive care admissions and deaths among cases. Further
142 details on the individual registries and data included in this study are presented in supplement
143 A, section 2.

144 We conducted a cohort study, including reported cases of COVID-19 aged <18 years who
145 tested positive from 15 March 2021 up to 30 January 2022, were unvaccinated at date of
146 positive test and had also not previously been diagnosed with COVID-19, and had a national
147 identity number registered. We extracted data up to 29 March 2022, ensuring a minimum 57
148 days of follow-up since last positive test.

149 **Definition of variant waves**

150 The national laboratory database houses data on SARS-CoV-2 test results from all Norwegian
151 microbiology laboratories. In Norway, SARS-CoV-2 variants are identified based on whole
152 genome sequencing, Sanger partial S-gene sequencing or PCR screening targeting specific
153 single nucleotide polymorphisms, insertions or deletions. The laboratory testing for variants
154 of SARS-CoV-2 in Norway has been described in further detail elsewhere (24). Using data
155 from the national laboratory database we identified different variant waves based on date of
156 positive test. The distribution of different variants among cases <18 years over time in
157 Norway is presented in Figure 1, with the underlying data available in supplement B. We
158 defined the Alpha dominant wave as week 11–20 (15 March–23 May) 2021, the Delta
159 dominant wave as week 35–48 (30 August–5 December) 2021 and the Omicron dominant
160 wave as week 2–4 (10–30 January) 2022. In the Omicron wave, sublineage BA.1 was
161 predominant (25).

162 **Severity outcome definitions**

163 Our severity outcomes of interest were: 1) admission to hospital with acute COVID-19
164 (regardless of main cause of admission) ≤ 14 days after positive test, 2) admission to hospital
165 ≤ 14 days after positive test where acute COVID-19 was the reported main cause of admission
166 and 3) admission to hospital with MIS-C, defined as patients registered with the International
167 Classification of Diseases-10 diagnosis code U10.9. Clinical criteria for the diagnosis of MIS-
168 C cases in Norway are based on the World Health Organisation case definition, as per
169 national paediatric guidelines (26).

170 **Data analysis**

171 We described cases by variant wave, severity outcome, demographic characteristics and
172 underlying comorbidities. We also described other outcomes among hospitalised patients
173 including length of stay (LoS) in hospital and admission to an intensive care unit (ICU), as
174 well as all deaths in the study cohort. For our three severity outcomes, we calculated adjusted
175 risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable log-binomial
176 regression. Explanatory variables to analyse differences in our outcomes included variant
177 wave (Alpha, Delta or Omicron), age (as continuous or categorical variable), sex, country of
178 birth, region of residence, and underlying comorbidities. The categorisation of explanatory
179 variables is presented in Table 1 and further detailed in Supplement A, section 2. Explanatory
180 variables were first checked in univariable models, and those with $p < 0.2$ were further
181 explored in multivariable models. Explanatory variables were further categorised in some
182 models to best fit the data, for example a dichotomous variable for underlying comorbidities
183 (yes/no). We maintained the variant wave variable in each multivariable analysis, even if not
184 significant. We used Akaike Information Criteria and the likelihood ratio test to check model
185 fit. We ran models for each variant combination (Delta vs. Alpha, Omicron vs. Alpha,
186 Omicron vs. Delta) for all cases < 18 years, as well as for the age subgroups < 1 , 1–11 and 12–
187 17 years. For the age group 12–17 years, we also conducted a sensitivity analysis, including

188 vaccinated cases and reinfections, and adjusting for vaccination status (supplement A, section
189 3). Further, we validated the variant wave variable by running models for all COVID-19 cases
190 reported in Norway, and comparing results to estimates based on cases with known variant
191 (supplement A, section 4). Statistical analysis was performed in Stata version 16 (Stata
192 Corporation, College Station, Texas, US).

193 **Ethics**

194 Ethical approval for studies on the risk of severe disease by SARS-CoV-2 variant based on
195 data from the national preparedness registry for COVID-19 was granted by Regional
196 Committees for Medical Research Ethics - South East Norway, reference number 249509.

197 **Results**

198 **Study cohort**

199 The total number of reported cases of COVID-19 aged <18 years was 10,620 during the
200 Alpha wave, 53,724 during the Delta wave and 133,383 during the Omicron wave. Of these,
201 10,541 (99.3%) Alpha, 53,576 (99.7%) Delta and 133,042 (99.7%) Omicron cases had a
202 known national identity number. Of these 10,538 (99.9%) Alpha, 42,362 (79.1%) Delta and
203 83,884 (62.3%) Omicron cases were included in the study cohort as they were unvaccinated at
204 date of positive test and had not been previously diagnosed with COVID-19. Detailed
205 characteristics of the study cohort by variant are presented in Table 1.

206 **Risk of hospitalisation**

207 Overall, 174 (0.1%) cases were hospitalised ≤ 14 days after positive test, of which 97 with
208 acute COVID-19 as main cause (0.07% of all cases in study cohort). Few additional
209 admissions >14 days after positive test were observed (Table 1). Of the 97, 48 (50%) were <1

210 year of age, 44 (45%) were female and 83 (86%) had no registered comorbidity. Of the 48 <1
211 year, 32 (67%) were <3 months of age, and 42 (88%) were <6 months of age.

212 In the Alpha, Delta and Omicron waves, 21 (0.2%), 28 (0.07%) and 48 (0.06%) cases <18
213 years were hospitalised with acute COVID-19 as main cause ≤ 14 days after positive test,
214 respectively (Table 1, Table 2). The risk of hospitalisation with acute COVID-19 as main
215 cause was lower in the Delta (aRR: 0.53, 95% CI: 0.30–0.93) and Omicron wave (aRR: 0.40,
216 95% CI: 0.24–0.68) compared to the Alpha wave. This was explained by the age group <1
217 year (aRR Delta compared to Alpha: 0.28, 95% CI: 0.16–0.89; aRR Omicron compared to
218 Alpha: 0.41, 95% CI: 0.20–0.81). Results also suggested a decreased risk in cases aged 1–11
219 years in the Omicron wave compared to the Alpha wave (aRR: 0.32, 95% CI: 0.13–0.83). We
220 did not observe any difference in the adjusted risk in any age group in the Omicron wave
221 compared to the Delta wave. Results for the outcome admission to hospital ≤ 14 days after
222 positive test regardless of main cause were largely consistent with those for acute COVID-19
223 as main cause of hospitalisation, although we did observe a decreased risk in cases <18 years
224 in the Omicron wave compared to Delta wave (aRR: 0.67, 95% CI: 0.48–0.94) (Table 2).

225 **Risk of MIS-C**

226 Twenty-eight cases of MIS-C were reported across the three waves (0.02% of all cases)
227 (Table 2). The median age was 6.5 years (interquartile range (IQR): 4–9.5; range 1–17), 12
228 (43%) were female and 26 (93%) had no registered comorbidity. In the Alpha, Delta and
229 Omicron waves, 7 (0.07%), 14 (0.03%) and 7 (0.008%) cases <18 years were diagnosed with
230 MIS-C, respectively (Table 1, Table 2). We did not observe a significant difference in the risk
231 of MIS-C in the Delta wave compared to the Alpha wave. The risk of MIS-C among cases
232 <18 years was lower in the Omicron wave compared to the Alpha (aRR: 0.09, 95% CI: 0.03–
233 0.27) and Delta wave (aRR: 0.26, 95% CI: 0.10–0.63) (Table 2).

234 **Length of hospital stay, admission to intensive care and death**

235 The median LoS among cases hospitalised with acute COVID-19 as main cause was 0.8 days
236 (IQR: 0.4–3.2) in the Alpha wave, 1.4 days (IQR: 0.7–3.1) in the Delta wave and 1.1 days
237 (IQR: 0.8–2.7) in the Omicron wave. Among the 28 MIS-C cases the median LoS was 4 days
238 (interquartile range (IQR): 2–6). Data on LoS is not presented by wave for MIS-C cases due
239 to the small number of MIS-C cases in each wave. Across all three waves, 6 (6%) cases
240 hospitalised with acute COVID-19 as main cause and 4 (14%) MIS-C cases were admitted to
241 ICU. This equates to 0.007% of reported cases being admitted to ICU for either acute
242 COVID-19 or MIS-C in Norway. At the end of follow-up, there were no reported deaths
243 among those hospitalised (either for acute COVID-19 or MIS-C), nor within 30 days of
244 positive test among those not hospitalised.

245 **Discussion**

246 We find no clear evidence of a difference in the risk of hospitalisation due to acute COVID-
247 19 among cases <18 years in the Omicron wave compared to the Delta wave. Our results are
248 in line with similar national studies from both England (5) and Denmark (12). The study in
249 England, which included over 300,000 COVID-19 cases and 1,500 hospitalisations <20 years,
250 did suggest a potentially small decrease in the risk of hospitalisation for Omicron compared to
251 Delta ≤ 14 days after positive test among unvaccinated 10–19-year-olds (adjusted hazard ratio:
252 0.78, 95% CI: 0.60–1.00). We did find a lower risk for hospitalisation regardless of main
253 cause in the Omicron wave compared to the Delta wave. However, our results for this
254 indicator should be interpreted with caution as it will include patients admitted for non-
255 COVID-19 related causes. We find no difference in the risk of hospitalisation with COVID-
256 19 as main cause in the Omicron wave compared to the Delta wave.

257 The risk of hospitalisation with acute COVID-19 among cases <1 year was lower in the Delta
258 and Omicron waves, compared to the Alpha wave. As the majority of hospitalised cases <1
259 year across the three waves were <3 months old, the decrease in risk may be related to
260 protection offered to infants born to mothers vaccinated during pregnancy (27). Vaccination
261 during pregnancy was first generally recommended in Norway before the start of the Delta
262 wave. Conversely, we did not see a difference in the risk of hospitalisation with acute
263 COVID-19 among cases <1 year between the Omicron and Delta waves. This may reflect
264 higher vaccination coverage among pregnant women, but lower vaccine effectiveness in the
265 Omicron wave (7).

266 Compared to other VOC, the Omicron variant has been shown to replicate more easily in the
267 upper respiratory tract but less well in the lungs (28). In this study we could not explore
268 whether the clinical presentation of children hospitalised with Omicron had changed,
269 compared to previous variant waves. There have been reports of an increase in upper
270 respiratory complications, such as croup, among young children since Omicron became
271 dominant (13, 14). Such changes in the clinical presentation of hospitalised paediatric
272 COVID-19 patients would have important implications for future hospital capacity planning
273 and management of paediatric patients as Omicron circulates.

274 Previous studies from the USA and Denmark estimated the incidence of MIS-C (defined
275 based on the case definition from the Centers for Disease Control and Prevention) to be
276 between 1 in 3,000 to 1 in 4,000 children infected with the wild-type SARS-CoV-2 variant
277 (29, 30). A subsequent study from Denmark found that this risk did not change among
278 unvaccinated cases during a wave of Delta infections (20). We find that the incidence of MIS-
279 C (based on the case definition from the World Health Organisation) in Norway during the
280 Delta wave was approximately 1 in 3,000 cases who were unvaccinated and had not been
281 previously diagnosed with COVID-19. This decreased to 1 in 12,000 in the Omicron wave, an

282 estimated 75% decrease (95% CI: 37%–90%) in risk. This may suggest a lower intrinsic risk
283 of MIS-C for Omicron compared to Delta. This is an encouraging finding, especially given
284 evidence that this risk may be further reduced through vaccination. Studies from Denmark
285 and the USA have estimated the effectiveness of two doses of Comirnaty[®] against MIS-C to
286 be 91%–94% during periods of Delta dominance (20, 31). In this study, when we included
287 vaccinated cases 12–17 years in a sensitivity analysis, no reported MIS-C cases had
288 completed a two-dose primary vaccination series ≥ 7 days before positive test (supplement A,
289 section 3). This is in line with another study from France (32). However, it remains to be seen
290 if the same level of vaccine effect against MIS-C is maintained during a period of Omicron
291 dominance. Omicron has been linked to an increase in breakthrough infections (7, 33) and
292 lower vaccine effectiveness against some severity outcomes among children and adolescents
293 5–17 years (34). The proportion of MIS-C cases admitted to ICU in our study is notably lower
294 than reported by others (11, 20, 35). Here, differences in the settings, definition of MIS-C
295 cases and the definition of ICU admission need to be considered. For example, our definition
296 of ICU admission will exclude stays in intermediate observation posts in a paediatrics unit.

297 In this study we have analysed national registry data from a setting with a broad COVID-19
298 testing strategy among children and adolescents. Hospitals in Norway functioned within
299 capacity during the study period. Criteria for hospitalisation and isolation for COVID-19
300 patients, and clinical criteria for the diagnosis of MIS-C, were consistent.

301 An important limitation with severity studies based on reported COVID-19 cases is that
302 undiagnosed cases will affect reported outcome proportions, while systematic differences in
303 undiagnosed cases between groups may affect comparisons. In our study, this is particularly
304 relevant for the comparison of the Alpha wave to other variant waves. The testing strategy
305 was enhanced after the Alpha wave, thus a higher proportion of asymptomatic and mild cases
306 may have been diagnosed among school-age children and adolescents in the Delta and

307 Omicron waves. Also, the small number of outcomes must be considered, which restricted
308 further exploration of our results. Given the low incidence of severe outcomes among child
309 and adolescent COVID-19 cases, which may be further reduced through vaccination (20, 31,
310 34, 36), analyses of pooled data from several countries or meta-analyses could provide more
311 precise estimates that can better elucidate differences in the risk of these outcomes between
312 VOC in younger age groups. Further, we have based the analysis on variant waves, not cases
313 with known data. However, in models for all COVID-19 cases reported in Norway, results
314 based on these waves were consistent with analyses based on cases with known variant in
315 periods when one variant was superseding another (see supplement A, section 4). Finally, we
316 analysed an Omicron wave when the sublineage BA.1 was the dominant circulating variant.
317 Further studies are still needed to establish differences in disease severity between different
318 Omicron sublineages.

319 **Conclusion**

320 We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19
321 among unvaccinated cases <18 years for Omicron compared to Delta in Norway, but a
322 reduced risk of hospitalisation among cases <1 year in Omicron and Delta waves, compared
323 to the Alpha wave. Results also suggest a decrease in the risk of MIS-C among those infected
324 with the Omicron variant compared to the Delta and Alpha variant.

325 **Acknowledgements**

326 First and foremost, we wish to thank all those who have helped establish and/or report data
327 housed in the national emergency preparedness registry for COVID-19 at the Norwegian
328 Institute of Public Health. We would also like to specifically thank Trude Lyngstad, Jostein
329 Starrfelt, Elina Seppälä, Mari Grøslund and ‘Team Riskgroup’ at the Norwegian Institute of
330 Public Health for their assistance in the cleaning of the data from the different registries, and
331 additionally Trude Lyngstad for her assistance in the production of Figure S1.

References

1. World Health Organisation. Tracking SARS-CoV-2 variants. 2022 [cited 2022 Mar 22]. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
2. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Euro Surveill.* 2021;26(24).
3. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CM, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *Medrxiv.* 2022. doi: <https://doi.org/10.1101/2022.01.28.22270044>
4. Veneti L, Seppala E, Larsdatter Storm M, Valcarcel Salamanca B, Alnes Buanes E, Aasand N, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 - May 2021. *PLoS One.* 2021;16(10):e0258513.
5. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet.* 2022. doi: [https://doi.org/10.1016/S0140-6736\(22\)00462-7](https://doi.org/10.1016/S0140-6736(22)00462-7)
6. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med.* 2021;385(7):585-94.
7. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med.* 2022. doi: <https://doi.org/10.1056/NEJMoa2119451>
8. Veneti L, Boas H, Brathen Kristoffersen A, Stalcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. *Euro Surveill.* 2022;27(4).
9. World Health Organisation. COVID-19 Weekly Epidemiological Update, Edition 81. 2022 [cited 2022 Mar 22]. Available at: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-march-2022>
10. Rubens JH, Akindede NP, Tschudy MM, Sick-Samuels AC. Acute covid-19 and multisystem inflammatory syndrome in children. *BMJ.* 2021;372:n385.
11. Harwood R, Yan H, Talawila Da Camara N, Smith C, Ward J, Tudur-Smith C, et al. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis. *EClinicalMedicine.* 2022;44:101287.
12. Bager P, Wohlfahrt J, Bhatt S, Edslev SM, Sieber RN, Ingham AC, et al. Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study. *SSRN.* 2022. doi: <http://dx.doi.org/10.2139/ssrn.4008930>

13. Martin B, Dewitt PE, Russell S, Sanchez-Pinto LN, Haendel MA, Moffitt R, et al. Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV2: a report from the National COVID Cohort Collaborative (N3C). *Medrxiv*. 2022. doi: <https://doi.org/10.1101/2022.01.27.22269865>
14. Tun ◻ EM, Shin CKJ, Usoro E, Thomas-Smith SE, Trehan I, Migita RT, et al. Croup during the COVID-19 Omicron Variant Surge. *Medrxiv*. 2022. doi: <https://doi.org/10.1101/2022.02.02.22270222>
15. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis*. 2021. doi: [https://doi.org/10.1016/S1473-3099\(21\)00475-8](https://doi.org/10.1016/S1473-3099(21)00475-8)
16. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. *CMAJ*. 2021;193(42):E1619-E25.
17. Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, et al. Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. *JAMA Netw Open*. 2022;5(2):e2143151.
18. Yilmaz Celebi M, Kiyemet E, Boncuoglu E, Sahinkaya S, Cem E, Duzgol M, et al. Evaluation of childhood hospitalization rates and degree of severity of SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.315/P.1 (Beta/Gamma), and B.1.617.2 (Delta). *J Med Virol*. 2022. doi: <https://doi.org/10.1002/jmv.27587>
19. Shoji K, Akiyama T, Tsuzuki S, Matsunaga N, Asai Y, Suzuki S, et al. Comparison of the clinical characteristics and outcomes of COVID-19 in children before and after the emergence of Delta variant of concern in Japan. *J Infect Chemother*. 2022;28(4):591-594.
20. Nygaard U, Holm M, Hartling UB, Glenthøy J, Schmidt LS, Nordly SB, et al. Multisystem Inflammatory Syndrome in Children Following the SARS-CoV-2 Delta Variant in Denmark: Clinical Phenotype and Risk by Vaccination Status and Compared to the Pre-Delta COVID-19 Era. *SSRN*. 2022. doi: <http://dx.doi.org/10.2139/ssrn.4031587>
21. Veneti L, Valcarcel Salamanca B, Seppala E, Starrfelt J, Storm ML, Bragstad K, et al. No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. *Int J Infect Dis*. 2022;115:178-84.
22. Norwegian Institute of Public Health. Coronavirus vaccine - information for the public. 2022 [cited 2022 Mar 22]. Available from: <https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/>
23. Norwegian Institute of Public Health. Emergency preparedness register for COVID-19 (Beredt C19). 2022 [cited 2022 Mar 22]. Available from: <https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/>
24. Norwegian Institute of Public Health. Påvisning og overvåkning av SARS-CoV-2-virusvarianter. Oslo: Norwegian Institute of Public Health. 2022 [cited 2022 Mar 22].

Available at: <https://www.fhi.no/nettpub/coronavirus/testing/pavisning-og-overvakning-av-sars-cov-2-virusvarianter/>

25. Norwegian Institute of Public Health. Ukerapport uke 7 2022. 2022 [cited 2022 Mar 22]. Available at: <https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdbf381ab52e6157/vedlegg/2022/ukerapport-uke-7-14.02---20.02.22.pdf>
26. Norwegian Society of Pediatricians. Inflammatorisk multisystemsyndrom ved covid-19 (MIS-C). 2022 [cited 2022 Mar 22]. Available at: <https://www.helsebiblioteket.no/pediatriveiledere?menuitemkeylev1=5962&menuitemkeylev2=5966&key=271455>
27. Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Boom JA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(7):264-70.
28. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature.* 2022. doi: <https://doi.org/10.1038/s41586-022-04479-6>
29. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. *JAMA Netw Open.* 2021;4(6):e2116420.
30. Holm M, Hartling UB, Schmidt LS, Glenthoj JP, Kruse A, Rytter MH, et al. Multisystem inflammatory syndrome in children occurred in one of four thousand children with severe acute respiratory syndrome coronavirus 2. *Acta Paediatr.* 2021;110(9):2581-3.
31. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. *MMWR Morb Mortal Wkly Rep.* 2022;71(2):52-8.
32. Levy M, Recher M, Hubert H, Javouhey E, Flechelles O, Leteurtre S, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. *JAMA.* 2022;327(3):281-3.
33. Chen LL, Chua GT, Lu L, Chan BP, Wong JS, Chow CC, et al. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. *Emerg Microbes Infect.* 2022;11(1):543-7.
34. Klein NP, Stockwell MS, Demarco M, Gaglani M, Kharbanda AB, Irving SA, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(9):352-8.

35. Miller AD, Zambrano LD, Yousaf AR, Abrams JY, Meng L, Wu MJ, et al. Multisystem Inflammatory Syndrome in Children-United States, February 2020-July 2021. Clin Infect Dis. 2021. doi: <https://doi.org/10.1093/cid/ciab1007>
36. Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. N Engl J Med. 2022;386(8):713-23.

332 **Tables and Figures**

333 *Figure 1. Reported COVID-19 cases aged <18 years in Norway with known and unknown*
334 *variant (bars, left y-axis), and proportion of cases with known variant that were the Alpha,*
335 *Delta or Omicron variant of concern (lines, right y-axis), by week, 1 January 2021 – 6*
336 *February 2022.*

337 The data behind the figure are available in supplement B. During the Alpha wave (week 11–
338 20 2021), the proportion of cases that were known to be infected with Alpha ranged from
339 86%–95% of cases with known variant, however, the vast majority of other cases with known
340 variant were reported as ‘probable variant of concern’. In Norway, there was minimal
341 circulation of other defined variants of concern (Beta, B.1.351 and Gamma, P.1), thus it is
342 reasonable to assume that most cases reported as ‘probable variant of concern’ were also the
343 Alpha variant. Taking these cases into account the proportion infected with Alpha among
344 those with known variant ranges from 94%–100% in the Alpha wave.

345 *Table 1. Characteristics of reported cases of COVID-19 aged <18 years who were*
 346 *unvaccinated and had also not previously been diagnosed with COVID-19, by variant wave,*
 347 *Norway, 15 March 2021 – 30 January 2022*

Characteristics		Variant wave		
		Alpha dominated wave (n=10,538)	Delta dominated wave (n=42,362)	Omicron dominated wave (n=82,907)
Included weeks		11–20 2021	35–48 2021	2–4 2022
Sex	Male	5118 (48.6%)	20575 (48.6%)	39835 (48.0%)
	Female	5420 (51.4%)	21787 (51.4%)	43072 (52.0%)
Age group	<1 year	267 (2.5%)	636 (1.5%)	1613 (1.9%)
	1-5 years	2317 (22.0%)	5484 (12.9%)	19516 (23.5%)
	6-11 years	3611 (34.3%)	22515 (53.1%)	50772 (61.2%)
	12-15 years	2643 (25.1%)	10191 (24.1%)	9648 (11.6%)
	16-17 years	1700 (16.1%)	3536 (8.3%)	1358 (1.6%)
Median age	In years (IQR)	10 (6–14)	10 (7–13)	8 (5–10)
Born in Norway	Yes, with at least one parent born in Norway	5510 (52.3%)	29143 (68.8%)	63225 (76.3%)
	Yes, two parents born outside of Norway	3425 (32.5%)	8387 (19.8%)	13121 (15.8%)
	No	1598 (15.2%)	4812 (11.4%)	6555 (7.9%)
	Unknown	5 (<0.1%)	20 (<0.1%)	6 (<0.1%)
Risk for severe COVID-19 ^a	No underlying comorbidities	9732 (92.4%)	39319 (92.8%)	77699 (92.6%)
	Medium-risk comorbidity	756 (7.2%)	2886 (6.8%)	5897 (7.0%)
	High-risk comorbidity	50 (0.5%)	178 (0.4%)	288 (0.3%)
Region of residence ^b	Southeast	8882 (84.3%)	29564 (69.8%)	57487 (69.3%)
	West	1265 (12.0%)	5033 (11.9%)	13831 (16.7%)
	Mid	287 (2.7%)	4669 (11.0%)	8255 (10.0%)
	North	94 (0.9%)	3057 (7.2%)	3270 (3.9%)
	Unknown	10 (<0.1%)	39 (<0.1%)	64 (<0.1%)
Admission to hospital	No	10507 (99.7%)	42303 (99.9%)	82819 (99.9%)
	Yes, ≤14 days after positive test	30 (0.3%)	58 (0.1%)	86 (0.1%)
	Yes, 15–28 days after positive test	1 (<0.1%)	1 (<0.1%)	2 (<0.1%)
Admission to hospital with COVID-19 as main cause of admission	No	10517 (99.8%)	42334 (99.9%)	82858 (99.9%)
	Yes, ≤14 days after positive test	21 (0.2%)	28 (<0.1%)	48 (<0.1%)
	Yes, 15–28 days after positive test	0 (0.0%)	0 (0.0%)	1 (<0.1%)
Diagnosed with MIS-C	No	10531 (99.9%)	42348 (100.0%)	82900 (100.0%)
	Yes	7 (<0.1%)	14 (<0.1%)	7 (<0.1%)

348 COVID-19: coronavirus disease; MIS-C: Multisystem Inflammatory Syndrome in Children;
 349 IQR: interquartile range.

350 ^a Risk for severe disease based on underlying comorbidities that are associated with a
351 medium- or high-risk of serious illness regardless of age. Medium-risk includes chronic liver
352 disease or significant hepatic impairment, immunosuppressive therapy as in autoimmune
353 diseases, diabetes, chronic lung disease including cystic fibrosis and severe asthma which
354 have required the use of high dose inhaled or oral steroids within the past year, obesity with a
355 body mass index (BMI) of ≥ 35 kg/m², dementia, chronic heart and vascular disease (with the
356 exception of high blood pressure) and stroke. High-risk includes having received an organ
357 transplant, immunodeficiency, hematological cancer in the last five years, other active
358 cancers, ongoing or recently discontinued treatment for cancer (especially
359 immunosuppressive therapy, radiation therapy to the lungs or cytotoxic drugs), neurological
360 or neuromuscular diseases that cause impaired cough or lung function (e.g., ALS and cerebral
361 palsy), Down syndrome and chronic kidney disease, or significant renal impairment. Further
362 details on the definitions used are provided in Supplement A, section 2.

363 ^b Southeast: counties Oslo, Viken, Innlandet, Agder, Vestfold and Telemark; West: counties
364 Vestland and Rogaland; Mid: counties Trøndelag, and Møre and Romsdal; North: counties
365 Nordland, and Troms and Finnmark.

366 *Table 2. Number of reported cases admitted to hospital for acute COVID-19 or MIS-C, and crude and adjusted risk ratios from log-binomial*
 367 *regression, by age group and variant wave, cases <18 years who were unvaccinated and had also not previously been diagnosed with COVID-*
 368 *19, Norway, 15 March 2021 – 30 January 2022*

	Alpha wave (week 11–20 2021)		Delta wave (week 35–48 2021)				Omicron wave (week 2–4 2022)					
Outcome: Admission to hospital ≤14 days after positive test												
Age group	Number of outcomes/cases	%	Number of outcomes/cases	%	Crude relative risk compared to Alpha wave (95% CI)	Adjusted relative risk compared to Alpha wave (95% CI)	Number of outcomes/cases	%	Crude relative risk compared to Alpha wave (95% CI)	Adjusted relative risk compared to Alpha wave (95% CI)	Crude relative risk compared to Delta wave (95% CI)	Adjusted relative risk compared to Delta wave (95% CI)
<1 year	14/267	5.2	17/636	2.7	0.51 (0.25– 1.02)	0.45 (0.22– 0.92) ^d	36/1613	2.2	0.42 (0.23– 0.78)	^a	0.83 (0.47– 1.47)	0.91 (0.52– 1.60) ^e
1-11 years	9/5928	0.2	25/27999	<0.1	0.59 (0.27– 1.26)	1.12 (0.52– 2.41) ^{b,c,d}	44/70288	<0.1	0.41 (0.20– 0.84)	0.49 (0.24– 1.00) ^{b,c}	0.70 (0.43– 1.14)	0.64 (0.39– 1.05) ^{b,c,d}
12-17 years	7/4343	0.2	16/13727	0.1	0.72 (0.30– 1.75)	0.91 (0.37– 2.24) ^{b,c}	6/11006	<0.1	0.34 (0.11– 1.01)	^a	0.47 (0.18– 1.19)	^a
All <18 years	30/10541	0.3	58/42362	0.1	0.48 (0.31– 0.75)	0.70 (0.46– 1.08) ^{b,c}	86/82907	0.1	0.36 (0.24– 0.55)	0.48 (0.31– 0.72) ^{b,c}	0.76 (0.54– 1.06)	0.67 (0.48– 0.94) ^{b,c}
Outcome: Admission to hospital with COVID-19 as main cause of admission ≤14 days after positive test												
<1 year	11/267	4.1	10/636	1.6	0.28 (0.16– 0.89)	^a	27/1613	1.7	0.41 (0.20– 0.81)	^a	1.06 (0.52– 2.18)	^a
1-11 years	6/5928	0.1	10/27999	<0.1	0.35 (0.13– 0.94)	0.72 (0.26– 2.03) ^{b,c}	18/70288	<0.1	0.25 (0.10– 0.61)	0.32 (0.13– 0.77) ^{b,c}	0.72 (0.33– 1.56)	0.62 (0.28– 1.37) ^{b,c}

					0.97	2.01) ^{b,c,d}			0.64	0.83) ^{b,c}	1.55)	1.35) ^{b,c,d}
12-17 years	4/4343	<0.1	8/13727	<0.1	0.63 (0.19– 2.10)	^a	3/11006	<0.1	0.30 (0.07– 1.32)	^a	0.47 (0.12– 1.76)	^a
All <18 years	21/10538	0.2	28/42362	<0.1	0.33 (0.19 – 0.58)	0.53 (0.30 – 0.93) ^{b,c}	48/82907	<0.1	0.29 (0.17 – 0.48)	0.40 (0.24 – 0.68) ^{b,c}	0.88 (0.55– 1.40)	0.76 (0.47– 1.23) ^{b,c}
Outcome: MIS-C												
<1 year	0/267	0.0	0/636	0.0	-	-	0/1613	0.0	-	-	-	-
1-11 years	6/5928	0.1	11/27999	<0.1	0.39 (0.14– 1.05)	^a	7/70288	<0.1	0.10 (0.03 – 0.29)	^a	0.25 (0.10 – 0.65)	^a
12-17 years	1/4343	<0.1	3/13727	<0.1	0.95 (0.10– 9.12)	^a	0/11006	0.0	-	-	-	-
All <18 years	7/10538	<0.1	14/42362	<0.1	0.50 (0.20– 1.23)	^a	7/82907	<0.1	0.13 (0.04 – 0.36)	0.09 (0.03 – 0.27) ^{b,e}	0.26 (0.10 – 0.63)	^a

369 COVID-19: coronavirus disease; MIS-C: Multisystem Inflammatory Syndrome in Children; 95% CI: 95% confidence interval.

370 ^a The crude model was the best model.

371 ^b Adjusted for age.

372 ^c Adjusted for underlying comorbidities.

373 ^d Adjusted for country of birth.

374 ^e Adjusted for region of residence.

